Biofrontera Inc. Files 8-K Report
Ticker: BFRIW · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1858685
Sentiment: neutral
Topics: disclosure, filing
Related Tickers: BFRI
TL;DR
Biofrontera filed an 8-K. Check for updates.
AI Summary
On June 24, 2024, Biofrontera Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself are detailed in the provided text.
Why It Matters
This filing indicates Biofrontera Inc. is providing updates or disclosures to the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate negative or positive financial implications presented in the text.
Key Players & Entities
- Biofrontera Inc. (company) — Registrant
- June 24, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40943 (commission_file_number) — SEC File Number
- 47-3765675 (irs_number) — IRS Employer Identification No.
- 120 Presidential Way, Suite 330 Woburn, Massachusetts 01801 (address) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is June 24, 2024.
In which state was Biofrontera Inc. incorporated?
Biofrontera Inc. was incorporated in Delaware.
What is Biofrontera Inc.'s SEC File Number?
Biofrontera Inc.'s SEC File Number is 001-40943.
What is the principal executive office address for Biofrontera Inc.?
The principal executive office address is 120 Presidential Way, Suite 330, Woburn, Massachusetts 01801.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-24 08:34:40
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- ex99-1_002.jpg (GRAPHIC) — 42KB
- ex99-2_003.jpg (GRAPHIC) — 157KB
- 0001493152-24-024881.txt ( ) — 568KB
- bfri-20240624.xsd (EX-101.SCH) — 4KB
- bfri-20240624_def.xml (EX-101.DEF) — 26KB
- bfri-20240624_lab.xml (EX-101.LAB) — 36KB
- bfri-20240624_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 7KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 120 Presidential Way , Suite 330 Woburn , Massachusetts 01801 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781) 245-1325 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Market LLC Preferred Stock Purchase Rights The Nasdaq Stock Market LLC Warrants to purchase common stock BFRIW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the "Exchange Act") (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD Disclosure On June 24, 2024, Biofrontera Inc. issued a press release announcing the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp. The full text of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information contained in Item 7.01 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. 99.1 Press release dated June 24, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. June 24, 2024 Biofrontera Inc. (Date) (Registrant) /s/ E. Fred Leffler III E. Fred Leffler III Chief Financial Officer